Ravinder N. Maini
About
In The Last Decade
Ravinder N. Maini
267 papers receiving 29.8k citations
Hit Papers
Peers
Comparison fields: 5 of 153
- Rheumatology 17.2k
- Immunology 10.2k
- Hematology 6.0k
- Radiology, Nuclear Medicine and Imaging 5.1k
- Molecular Biology 5.1k
Countries citing papers authored by Ravinder N. Maini
This map shows the geographic impact of Ravinder N. Maini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravinder N. Maini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravinder N. Maini more than expected).
Fields of papers citing papers by Ravinder N. Maini
This network shows the impact of papers produced by Ravinder N. Maini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravinder N. Maini. The network helps show where Ravinder N. Maini may publish in the future.
Co-authorship network of co-authors of Ravinder N. Maini
This figure shows the co-authorship network connecting the top 25 collaborators of Ravinder N. Maini. A scholar is included among the top collaborators of Ravinder N. Maini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravinder N. Maini. Ravinder N. Maini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis. | 1 |
| 4 | TNF as a therapeutic target | 2 |
| 5 | 100 | |
| 6 | Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. | 440 |
| 7 | 11 | |
| 8 | 2 | |
| 9 | 196 | |
| 10 | Sequence analysis of immunoglobulin heavy-chain variable region genes from the synovium of a rheumatoid arthritis patient shows little evidence of mutation but diverse CDR3. | 13 |
| 11 | 5 | |
| 12 | Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis breakdown → | 521 |
| 13 | 1 | |
| 14 | 44 | |
| 15 | Anti-La (SS-B): a diagnostic criterion for Sjögren's syndrome? | 33 |
| 16 | 17 | |
| 17 | Mixed reverse solid phase passive anti globulin hem adherence a simple new method of measurement of rheumatoid factors of all ig classes | 1 |
| 18 | 45 | |
| 19 | Human transfer factor in vitro. I. Augmentation of lymphocyte transformation to tuberculin PPD | 19 |
| 20 | 9 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.